Compare Organon & Co. Common Stock (OGN) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PubMatic Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while PubMatic Inc trades at $17.61 (market cap $860.90M). The key difference: Organon & Co. Common Stock is far larger — about 4.2× PubMatic Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PubMatic Inc for 40 Days on average.
| OGN | PUBM | |
|---|---|---|
Market Cap | $3.62B | $860.90M |
Volume | 2,892,999 | 528,167 |
Sector | Health | Technology |
52-Week High | $13.81 | $19.18 |
52-Week Low | $5.70 | $6.28 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $11.04B | $764.03M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PUBM trades at $17.64, down 4.75% today but maintains strong technical momentum with bullish moving average signals. The company reported three consecutive quarterly EPS beats despite negative annual net income margins. Recent Q2 2026 results showed 10.5% revenue growth and a significant EPS beat of $0.12 versus $0.03 expected, driven by mobile app and CTV segment strength.
Wall Street maintains bullish sentiment with 11 buy ratings and a $19.89 consensus target, representing 13% upside. Key risks include CFO transition uncertainty and competitive ad-tech landscape pressure. The stock's premium valuation (P/E 132) requires continued execution on AI-driven growth initiatives to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
